A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

Repurposing avoids the long, sometimes multi-decade process of developing and approving a new drug for a specific indication, ...

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, ...

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...

Seaport Therapeutics and Hemab Therapeutics on Thursday became the latest drugmakers to debut on Wall Street, continuing a ...

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the ...

The therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug ...

Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased ...